Brain AVM drug trial pulled before it began
NCT ID NCT06098872
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study aimed to see if the oral drug trametinib could improve the structure of brain arteriovenous malformations (AVMs) in adults before their scheduled surgery. The goal was to shrink the AVM or reduce risky features. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trametinib (oral tablet)
- What this could lead to
- If it had worked, trametinib might have made brain AVMs smaller or safer before surgery, potentially reducing surgical risks.
- What could go wrong
- The study was withdrawn before any participants were enrolled, so no data exist. Even if conducted, it was a small pilot with no guarantee of benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIOVENOUS MALFORMATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Health Network
Toronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive HHT registry aims to unlock secrets of rare bleeding disorder
- Could a transplant drug shrink dangerous blood vessel tangles?
- Massive study aims to predict brain surgery success
- New study tracks pregnancy dangers in rare vascular conditions
- New hope for rare blood vessel disorders: everolimus trial launches
- New hope for rare vascular malformations: targeted drugs enter trial